TLR7 tolerance is independent of the type I IFN pathway and leads to loss of anti-tumor efficacy in mice-Reference-Cited by-同舟云学术

TLR7 tolerance is independent of the type I IFN pathway and leads to loss of anti-tumor efficacy in mice

Published:2015-06-20 Issue:10 Volume:64 Page:1229-1239
ISSN:0340-7004
Container-title:Cancer Immunology, Immunotherapy
language:en
Short-container-title:Cancer Immunol Immunother

Author:

Koga-Yamakawa Erina,Murata Masashi,Dovedi Simon J.,Wilkinson Robert W.,Ota Yosuke,Umehara Hiroki,Sugaru Eiji,Hirose Yuko,Harada Hideyuki,Jewsbury Philip J.,Yamamoto Setsuko,Robinson David T.,Li Chiang J.

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Immunology,Immunology and Allergy

Link

http://link.springer.com/content/pdf/10.1007/s00262-015-1730-4.pdf

Reference34 articles.

1. Mangsbo SM, Ninalga C, Essand M, Loskog A, Totterman TH (2008) CpG therapy is superior to BCG in an orthotopic bladder cancer model and generates CD4 + T-cell immunity. J Immunother 31(1):34–42. doi: 10.1097/CJI.0b013e3181587d29

2. Koga-Yamakawa E, Dovedi SJ, Murata M, Matsui H, Leishman AJ, Bell J, Ferguson D, Heaton SP, Oki T, Tomizawa H, Bahl A, Takaku H, Wilkinson RW, Harada H (2013) Intratracheal and oral administration of SM-276001: a selective TLR7 agonist, leads to antitumor efficacy in primary and metastatic models of cancer. Int J Cancer 132(3):580–590. doi: 10.1002/ijc.27691

3. Geisel J, Kahl F, Muller M, Wagner H, Kirschning CJ, Autenrieth IB, Frick JS (2007) IL-6 and maturation govern TLR2 and TLR4 induced TLR agonist tolerance and cross-tolerance in dendritic cells. J Immunol 179(9):5811–5818

4. Hayashi T, Gray CS, Chan M, Tawatao RI, Ronacher L, McGargill MA, Datta SK, Carson DA, Corr M (2009) Prevention of autoimmune disease by induction of tolerance to toll-like receptor 7. Proc Natl Acad Sci USA 106(8):2764–2769. doi: 10.1073/pnas.0813037106

5. Bourquin C, Hotz C, Noerenberg D, Voelkl A, Heidegger S, Roetzer LC, Storch B, Sandholzer N, Wurzenberger C, Anz D, Endres S (2011) Systemic cancer therapy with a small molecule agonist of toll-like receptor 7 can be improved by circumventing TLR tolerance. Cancer Res 71(15):5123–5133. doi: 10.1158/0008-5472.CAN-10-3903

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. DSP-0509, a TLR7 agonist, exerted synergistic anti-tumor immunity combined with various immune therapies through modulating diverse immune cells in cancer microenvironment;Frontiers in Oncology;2024-09-13

2. TLR7 agonist, DSP-0509, with radiation combination therapy enhances anti-tumor activity and modulates T cell dependent immune activation;BMC Immunology;2024-07-25

3. Harnessing innate immune pathways for therapeutic advancement in cancer;Signal Transduction and Targeted Therapy;2024-03-25

4. DSP-0509, a systemically available TLR7 agonist, exhibits combination effect with immune checkpoint blockade by activating anti-tumor immune effects;Frontiers in Immunology;2023-01-30

5. In vitro characterization of immune modulating drug-eluting immunobeads towards transarterial embolization in cancer;Scientific Reports;2022-12-19